We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Medtronic Handed Form 483 on CAPAs, Inspections

Medtronic Handed Form 483 on CAPAs, Inspections

August 22, 2014

Medtronic Navigation was handed a six-observation Form 483 for issues related to CAPA, supplier investigations and quality inspections.

For example, the company had not validated accuracy acceptance testing for its S7 Surgeon Touch Monitor, which helps locate anatomical structures in open or percutaneous procedures. Medtronic classified the testing as a business need, rather than a user need, according to the form. However, the FDA’s review of complaint files for 2013 showed six that appeared to report accuracy issues with the monitor.

FDA investigators also reviewed five nonconformance reports, finding three that lacked documentation of a supplier investigation. While the company’s procedure states reworked material must be reinspected, an NCR requiring rework lacked documentation of a reinspection.

Meanwhile, the company’s standard operating procedure for unused, returned product did not state when a quality inspection of the product is necessary or address the disposition of returned goods. The investigators reviewed returned goods authorizations, finding six where products were returned to inventory with no documentation of inspection, testing or other verification.

They also reviewed documentation on the initial validation of the GoldenEye Calibration Robot, finding nothing on challenge tests for worst-case conditions or performance under a variety of process parameters.

Medtronic’s CAPA procedure also drew investigators’ attention. According to the procedure, once a CAPA has moved into the action execution phase, it can no longer receive a “no further action required” designation. However, two CAPA files with documentation of actions were classified as “closed-no action” and no effectiveness checks were performed, the form says.

Moreover, the company’s procedure states that CAPA timeliness is ensured by monitoring the progression of the CAPA phases, but eight files had investigation initiation dates 30 days or more after the creation log date of the CAPA file, the Form 483 adds.

Medtronic did not provide a comment on the Form 483.

Wondering what would improve your device company’s CAPA performance? We have answers from an exclusive, FDAnews survey of devicemakers, the Medical Device Manufacturer CAPA Benchmarking Survey.

Inspections and Audits

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing